Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ)

CNY 6.63

(0.45%)

Market Cap (In CNY)

6.98 Billion

Revenue (In CNY)

1.59 Billion

Net Income (In CNY)

327.87 Million

Avg. Volume

13.07 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.9-7.6
PE
-
EPS
-
Beta Value
0.23
ISIN
CNE100000JZ3
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Yingbin Zhou
Employee Count
-
Website
https://www.xykb.com
Ipo Date
2010-01-08
Details
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongdan dropping pills that clears heat, calms liver, and improves eyesight. The company was founded in 2000 and is based in Shanghai, China.